Showing results (71-80 of 118) with videos related to
Sort By:
Pageof 12
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK studyShirish M Gadgeel, Rimas V Lukas, Jerome Goldschmidt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 StudyJhanelle E Gray, Joel W Neal, Jyoti D Patel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller, Gregory J Riely, Maureen F Zakowski, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2021
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC StudyChristine M Bestvina, Kelli B Pointer, Theodore Karrison, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyMartin Reck, Jyoti D Patel, Jhanelle E Gray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2021
Management of Stage III Non-Small-Cell Lung Cancer: ASCO GuidelineMegan E Daly, Navneet Singh, Nofisat Ismaila, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung CancersJulia Rotow, Jyoti D Patel, Matthew P Hanley, et al.Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.Clinical Lung Cancer|June 29, 2025
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation StatusLyudmila Bazhenova, J G Hodgson, D Ross Camidge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2022
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800AKaren L Reckamp, Mary W Redman, Konstantin H Dragnev, et al.Pageof 12